Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-08-07

FDA Approved: UMECLIDINIUM AND VILANTEROL ELLIPTA — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved Prasco Laboratories' supplemental application to market a generic umeclidinium bromide and vilanterol triflate inhalation combination (Ellipta) for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • UMECLIDINIUM AND VILANTEROL ELLIPTA (umeclidinium bromide and vilanterol triflate)

Snippet

SUPPL AP for UMECLIDINIUM AND VILANTEROL ELLIPTA (UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE)